Drug Trial Radar · NCT06619483
A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants
Last checked: Nov 20, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 10, 2024
Primary completion
Jan 24, 2025
Study completion Jan 24, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events. Acute venous and arterial thrombotic and thromboembolic events refer to blood clots that form and cause blockages in blood vessels that may cause serious complications. The study treatment BAY3018250 is under development to treat acute venous and arterial thrombotic and thromboembolic events. It works by dissolving blood clots. In this study, participants will be healthy and will not benefit from BAY3018250. However, the study will provide information about how to test BAY3018250 in future studies of people with acute venous and arterial thrombotic and thromboembolic events. The results of this study will help in the future development of BAY3018250 as a treatment option for participants with acute venous and arterial thrombotic and thromboembolic events. It will also help in learning more about the drug when given to Chinese participants and helps in involving Chinese sites in clinical trials, to obtain approval for BAY3018250 in China. The main purpose of this study is to check if BAY3018250 is safe for further testing. For this, researchers will study the number and severity of medical problems participants have after receiving different amounts of BAY3018250. These medical problems are also known as adverse events. Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatment. In this study, there will be two groups. In each group, participants will be randomly assigned to receive a single dose of either BAY3018250 or placebo as an infusion into a vein, on Day 1. A placebo looks like a study drug but does not have any medicine in it. In the first group, participants will receive a low dose of BAY3018250. If researchers consider this dose to be safe, the next group will receive a higher dose. Each participant will be in the study for around 14 weeks, which includes: a visit to the clinic within 21 days before taking any treatment to confirm if the participant can take part in the study a hospital stay for around 7 days, during which participants will take their assigned treatment and have blood samples taken to check for drug levels five follow-ups on Day 10, Day 14, Day 28, Day 42, and Day 75. The last follow-up might be done by phone During the study, the doctors and their study team will: collect blood samples from the participants to measure the levels of the study drug given check participants' health by performing blood and urine tests, measuring the blood pressure, pulse rate and body temperature, and checking heart health using an electrocardiogram (ECG) ask the participants questions about how they are feeling and what adverse events they are having As this study is conducted in healthy participants who will not benefit from the treatment, access to the treatment after the study is not planned.
Conditions
- Acute Venous and Arterial Thrombotic and Thromboembolic Events
- Healthy Volunteers
Interventions
BAY3018250 Dose 1Drug
Single dose
PlaceboDrug
Matching placebo to BAY3018250
BAY3018250 Dose 2Drug
Single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experienced treatment-emergent adverse events (TEAEs) and drug-related TEAEs after administration of BAY3018250Time frame: Administration of study intervention until last follow-up visit (approximately 75 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou University of TCM
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.